T. Rowe Price Associates’s Generation Bio GBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-209,641
Closed -$1.19M 3162
2025
Q4
$1.19M Sell
209,641
-367,148
-64% -$2.07M ﹤0.01% 2007
2025
Q3
$3.53M Sell
576,789
-269,472
-32% -$1.4M ﹤0.01% 1511
2025
Q2
$2.71M Sell
846,261
-59,923
-7% -$231K ﹤0.01% 1511
2025
Q1
$3.67M Sell
906,184
-21,722
-2% -$153K ﹤0.01% 1355
2024
Q4
$9.84M Sell
927,906
-7,253
-0.8% -$129K ﹤0.01% 1155
2024
Q3
$23.1M Sell
935,159
-16,204
-2% -$429K ﹤0.01% 965
2024
Q2
$26.8M Buy
951,363
+63,527
+7% +$2.06M ﹤0.01% 883
2024
Q1
$36.1M Buy
887,836
+195,219
+28% +$4.6M ﹤0.01% 813
2023
Q4
$11.4M Sell
692,617
-52,853
-7% -$922K ﹤0.01% 1068
2023
Q3
$28.3M Sell
745,470
-3,948
-0.5% -$187K ﹤0.01% 834
2023
Q2
$41.2M Sell
749,418
-15,002
-2% -$688K 0.01% 757
2023
Q1
$32.9M Buy
764,420
+38,315
+5% +$1.85M ﹤0.01% 799
2022
Q4
$28.5M Sell
726,105
-13,452
-2% -$706K ﹤0.01% 822
2022
Q3
$39.3M Sell
739,557
-153,604
-17% -$9.61M 0.01% 721
2022
Q2
$58.6M Buy
893,161
+16,792
+2% +$1.1M 0.01% 827
2022
Q1
$64.3M Buy
876,369
+11,657
+1% +$675K 0.01% 884
2021
Q4
$61.2M Buy
864,712
+1,890
+0.2% +$330K 0.01% 937
2021
Q3
$216M Buy
862,822
+126,510
+17% +$30.3M 0.02% 528
2021
Q2
$198M Buy
736,312
+87,858
+14% +$26.3M 0.02% 559
2021
Q1
$185M Buy
648,454
+209,036
+48% +$66.9M 0.02% 577
2020
Q4
$125M Buy
439,418
+7,322
+2% +$2.35M 0.01% 662
2020
Q3
$129M Buy
432,096
+13,978
+3% +$3.34M 0.01% 588
2020
Q2
$84.6M Buy
+418,118
New +$93.1M 0.01% 683

Other funds holding GBIO

T. Rowe Price Associates's GBIO Position: Q1 2026 in Review

T. Rowe Price Associates sold out of Generation Bio (GBIO) in Q1 2026, closing a stake of 209,641 shares — an estimated $1.19M sold.

T. Rowe Price Associates first reported a position in GBIO in Q2 2020 and held it in 23 quarters. The position peaked at $216M in Q3 2021. 2 funds tracked by Wall St. Rank hold GBIO as of Q1 2026.

  • T. Rowe Price Associates reported no remaining Generation Bio position as of Q1 2026 after selling out during the quarter.
  • T. Rowe Price Associates sold 209,641 Generation Bio shares in Q1 2026, an estimated $1.19M.
  • T. Rowe Price Associates first reported a position in Generation Bio in Q2 2020 and held it in 23 quarters.
  • T. Rowe Price Associates's Generation Bio position peaked at $216M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Generation Bio as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.